Faivre B, Menu P, Labrude P, Vigneron C
Laboratoire d'Hématologie-Physiologie, Faculty of Pharmacie, University Henri Poincaré-Nancy I, France.
Artif Cells Blood Substit Immobil Biotechnol. 1998 Jan;26(1):17-26. doi: 10.3109/10731199809118943.
The amount of circulating methemoglobin in healthy humans is the result of a balance between methemoglobin production (from autooxidation and oxidation) and hemoglobin reduction. Hemoglobin autooxidation and oxidation are very complex and are not well understood. This article analyses the literature on hemoglobin autooxidation, oxidation and reduction and sets out a sequence of reactions for the oxidation of hemoglobin and the ways in which the percentage of methemoglobin is regulated or methemoglobin production prevented. Most of the information concerns erythrocyte hemoglobin, but plasma extracellular hemoglobin (from hemolysis or hemoglobin-based blood substitutes) is also considered where possible.
健康人体内循环高铁血红蛋白的含量是高铁血红蛋白生成（源于自身氧化和氧化作用）与血红蛋白还原之间平衡的结果。血红蛋白的自身氧化和氧化作用非常复杂，目前尚未完全了解。本文分析了有关血红蛋白自身氧化、氧化和还原的文献，并阐述了血红蛋白氧化的反应序列以及调节高铁血红蛋白百分比或防止高铁血红蛋白生成的方式。大部分信息涉及红细胞血红蛋白，但也尽可能考虑了血浆细胞外血红蛋白（来自溶血或基于血红蛋白的血液替代品）。
